Structure via PubChem · Public domain (PubChem)
moxaverine
Sign in to saveMoxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor, and on its influence on the rheological properties of red blood cells.
Chemical data
- Formula
- C20H21NO2
- Molecular weight
- 307.4 g/mol
- IUPAC name
- 1-benzyl-3-ethyl-6,7-dimethoxyisoquinoline
- SMILES
- CCC1=NC(=C2C=C(C(=CC2=C1)OC)OC)CC3=CC=CC=C3
- InChIKey
- MYCMTMIGRXJNSO-UHFFFAOYSA-N
- XLogP
- 4.8
- Polar surface area
- 31.4 Ų
- H-bond donors
- 0
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- ischemia, gastrointestinal disease
via ChEMBL · EBI
Research
24 papers- The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects.Acta ophthalmologica · 2012
- Effects of orally administered moxaverine on ocular blood flow in healthy subjects.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2013
- Effect of systemic moxaverine on ocular blood flow in humans.Acta ophthalmologica · 2009
- Redox-Neutral Manganese(I)-Catalyzed C-H Activation: Traceless Directing Group Enabled Regioselective Annulation.Angewandte Chemie (International ed. in English) · 2017
- Tissue distribution of moxaverine-hydrochloride in the rabbit eye and plasma.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2005
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 307.157
Show 5 more facts
- chemical formula
- C₂₀H₂₁NO₂
- canonical SMILES
- CCC1=CC2=CC(=C(C=C2C(=N1)CC3=CC=CC=C3)OC)OC
- subject has role
- parasympatholytic
- Commons category
- Moxaverine
- defined daily dose
- 50
Sources (3)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor, and on its influence on the rheological properties of red blood cells.
Moxaverine hydrochloride (Kollateral forte®, Ursapharm. Saarbrücken, Germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion. The ocular efficacy of moxaverine has been explored in the clinic.
Excerpted from Wikipedia’s “moxaverine” article, available under the CC BY-SA 4.0 licence.